Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02605174 · ClinicalTrials.gov registry record · Phase 3
Three Doses of Lasmiditan (50 mg, 100 mg and 200 mg) Compared to Placebo in the Acute Treatment of Migraine
A Phase 3 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 3,005
- Enrollment target
NCT02605174: Completed Phase 3 study, sponsored by Eli Lilly and Company.
NCT02605174 is a Phase 3 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 3,005 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (289% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02605174, a Phase 3 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 3,005 participants
- Enrollment target
Study Summary
This is a prospective randomized, double-blind, placebo-controlled study in participants with disabling migraine (Migraine Disability Assessment (MIDAS) score ≥ 11).
Primary Outcome
The percentage of participants defined as mild, moderate, or severe headache pain becoming none.
Interventions
- DRUG Placebo
- DRUG Lasmiditan 50 mg
- DRUG Lasmiditan 100 mg
- DRUG Lasmiditan 200 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,005 participants |
| Start Date | 2016-05 |
| Est. Completion | 2017-06-30 |
| Phase | Phase 3 |
What the finished NCT02605174 record still lists
NCT02605174 is an interventional study that assigns participants to a tested intervention. Its 3,005 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (289% higher).
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT02605174 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02605174 about?
NCT02605174 is a clinical study titled "Three Doses of Lasmiditan (50 mg, 100 mg and 200 mg) Compared to Placebo in the Acute Treatment of Migraine". This is a prospective randomized, double-blind, placebo-controlled study in participants with disabling migraine (Migraine Disability Assessment (MIDAS) score ≥ 11).
What is the current status of trial NCT02605174?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 3,005 participants. The study started on 2016-05. Estimated completion is 2017-06-30.
What interventions are being tested in trial NCT02605174?
The interventions under investigation include: Placebo (DRUG), Lasmiditan 50 mg (DRUG), Lasmiditan 100 mg (DRUG), Lasmiditan 200 mg (DRUG).
Who is sponsoring clinical trial NCT02605174?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02605174's enrollment target sits among peer trials
3,005 79th of 2000 higher than 1,922 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00004847 · 3,000 participants · Phase 1
Diagnosis of Pheochromocytoma
- NCT00478712 · 3,000 participants
Hirschsprung Disease Genetic Study
- NCT00579566 · 3,000 participants
Novel Biochemical and Molecular Determinants for Soft Tissue Sarcoma
- NCT00816114 · 3,000 participants
Chart Review Study of Chronic Myelogenous Leukemia (CML) Patients Treated With Imatinib Outside of a Clinical Trial
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia